Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP045052priorityCriticalpatent/ECSP045052A/en
Publication of ECSP045052ApublicationCriticalpatent/ECSP045052A/en
Se proporciona una composición farmacéutica para el tratamiento de condiciones en mamíferos que son sensibles a inhibición de COX-2 que comprende en combinación un inhibidor de COX-2 y aspirina a dosis baja para uso simultáneo, secuencial o separado.A pharmaceutical composition is provided for the treatment of conditions in mammals that are sensitive to COX-2 inhibition comprising in combination a COX-2 inhibitor and low dose aspirin for simultaneous, sequential or separate use.
ECSP0450522004-04-082004-04-08
COMBINATIONS THAT INCLUDE COX-2 AND ASPIRINE INHIBITORS
ECSP045052A
(en)
Use of a composition comprising an h1 antagonist, and an anti-tnf alpha compound to treat allergic conjunctivitis or allergic rhinitis in a human subject
Compounds derived from piperidine-carboxamide, renin inhibitors; pharmaceutical composition that includes them; and use in the treatment or prevention of a circulatory disease, hypertension and / or various organic damages attributable to hypertension.
COMPOUNDS DERIVED FROM HETEROCICLES REPLACED WITH MORFOLINA, INHIBITORS OF THE ACTIVITY OF PI3 QUINASA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; PHARMACEUTICAL KIT; AND ITS USE IN THE CANCER PROFILACTIC OR THERAPEUTIC TREATMENT
COMPOUNDS DERIVED FROM HETEROCICLES REPLACED WITH MORFOLINA, INHIBITORS OF THE PI3 QUINASA ACTIVITY; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; PHARMACEUTICAL KIT; AND ITS USE FOR CANCER PROFILACTIC OR THERAPEUTIC TREATMENT.
Use of a composition comprising a compound derived from heterocycle to treat or prevent the loss of intestinal flow; composition comprising said compound; and kit that includes the composition.
Use of specific sgc stimulating and / or activating compounds; pharmaceutical formulation comprising said compounds; kit comprising the compounds, and use for the prevention and / or treatment of systematic sclerosis.
Compounds derived from quinoline or benzopyran hiv replication inhibitors; pharmaceutical composition comprising said compounds; and its use in the treatment of a hiv infection
A phosphodiesterase 7 (pde7) inhibitory agent to be used in the treatment or reduction of the possibility of an addiction; and pharmaceutical composition, unit dosage form and pharmaceutical kit including phosphodiesterase 7 inhibitor (pde7) and an additional therapeutic agent.
Pharmaceutical formulation for topical application on the skin comprising an oil-in-water emulsion and the compound (r) -3-cyclopentyl-3- [4- (7h-pyrrolo [2,3-d] pyrimidin-4-yl) - 1h-pyrazol-1-yl] propanonitrile, jak1 / jak2 inhibitor; method to treat a skin disorder; and its use in the treatment of a skin disorder.
Compounds derived from nitrogen heterocycles, antagonists of apoptosis protein inhibitors; its pharmaceutical compositions; and use of said compounds for the treatment of cancer.
Compounds derived from pyrimidin-2-yl-1h-indole, atr protein kinase inhibitors; pharmaceutical composition comprising one of the compounds; and use of the compounds in the preparation of useful medicines for the treatment of cancer.
A method for treating an infection in a subject comprising the administration of 9 - [(2,2-dimethyl-propylamino) -methyl] -minocycline or a salt thereof; pharmaceutical composition comprising said compound; and its use.
Compounds derived from resolviin; pharmaceutical composition; use of the composition; pharmaceutical kit; pharmaceutical combination; use of the compounds in the treatment and / or prevention of an ophthalmic condition.
Compounds derived from pyridin-3-yl-oxypyridin-2-yl-amino, alk5 inhibitors; pharmaceutical composition comprising said compound; and use of the compound in the treatment of cancer.
Compounds derived from substituted 1H-pyrazoles, inhibitors of kinase-catalyzed reactions; its preparation procedure; pharmaceutical composition; intermediate compounds; use of the main compounds, useful in the treatment of cancer.